

Table of Contents

1.0 INTRODUCTION	1
1.1 Purpose	2
1.2 Scope	3
2.0 ABBREVIATIONS	4
3.0 EXISTING GUIDANCE DOCUMENTS FOR VACCINES... 	4
4.0 CONTROL STRATEGY FROM PROCESS DEVELOPMENT TO VACCINE LIFECYCLE MANAGEMENT	6
4.1 Key Elements and Considerations for Establishing Vaccines Control Strategy.....	6
4.2 Considerations for Setting and Managing Vaccine Specifications	7
4.2.1 Considerations for Setting Vaccine Specifications: Critical Quality Attributes and Ranges	7
4.2.2 Approaches for Analytical Procedures Selection in Specifications	9
4.2.3 Managing Vaccine Specifications throughout Product Lifecycle.....	10
4.3 Establishing Process Parameter Classifications and Lifecycle Management	10
4.3.1 Considerations for Establishing Process Parameter Classifications	10
4.3.2 Considerations for Reclassification of Parameters	11
5.0 COMPARABILITY ASSESSMENTS: ENABLER FOR CHANGES DURING DEVELOPMENT AND AFTER APPROVAL	12
5.1 Benefits of Comparability Protocols and Comparability Exercises for Vaccines.....	12
6.0 CONSIDERATIONS FOR VACCINES LIFECYCLE MANAGEMENT	19
6.1 Nonregulatory Considerations for Management of Post-Approval Changes	20
6.1.1 Technical Considerations for Management of Changes	20
6.1.2 Validation Considerations for Management of Changes	26
6.1.3 Relying on Effective Pharmaceutical Quality System for Management of Changes.....	29
6.1.4 Use of a Risk-Based Approach and Development of an Effective PQS	29
6.2 Regulatory Considerations for Management of Post-Approval Changes	30
6.2.1 General Regulatory Considerations for Management of PACs.....	31
6.2.2 Key Considerations for Post-Approval Change Submissions	32
6.2.3 Using the Regulatory Mechanism of ICH Q12.....	33
6.2.4 Strategies for Multinational and Multiproduct Submissions	36
7.0 CONCLUSION	37
8.0 REFERENCES.....	38

FIGURES AND TABLES INDEX

Figure 1.0-1	Complexity of Vaccine Development and Lifecycle Management.....	1
Table 1.0-1	Diversity in Vaccine Platforms	2
Table 3.0-1	Summary of Selected Guidance and Industry Documents and Relevance to Strategies for Vaccines Development and Lifecycle Management.....	5
Figure 4.1-1	Holistic Control Strategy for Vaccines Development and Lifecycle	6
Table 4.2.1-1	Examples of Quality Attributes with Additional Considerations for Vaccines.....	8
Table 4.3.2-1	Examples of Parameter Classification Changes	11
Table 5.2-1	Examples where Vaccine Changes Could be Justified with Analytical or Target Clinical Data	14
Table 5.3-1	Examples of Quality Attributes that Could Leverage Analytical Comparability.....	15
Table 5.3-2	Examples where Comparability could be Considered without Need for Additional Clinical Studies.....	15
Table 5.3-3	Examples when Clinical Data may be Required to Support Comparability.....	16
Table 5.4-1	Practical Considerations for Comparability Assessments	16
Figure 5.4-2	Timing of Implementation Using	

Table 5.4-2	Comparability Protocol 18	Table 6.1.2.3-1	Matrix Approach using Three Strategies 27
	Common Comparability Protocols		
	Received by U.S. FDA, 2004-2014..... 18	Figure 6.1.2.3-1	Representation of Matrix Validation Approach 28
Figure 6.0-1	Representation of the Complexity in Managing Multinational Regulatory Submissions..... 19	Table 6.1.2.3-2	Illustration of a Matrix Approach for Filling Process PPQ 28
Figure 6.0-2	Vaccine Inventory Complexity Management 20	Figure 6.1.4-1	Risk-Based Assessment of PACs and Determination of Regulatory Reporting Category 30
Figure 6.1-1	Vaccine Lifecycle Management Complexity..... 21	Table 6.2.1-1	Overview of the Current Situation and Proposals for Improvement..... 32
Table 6.1.1.2-1	Examples of Working Cell Bank Manufacturing Changes, Potential Classification, and Supporting Data Expectations 23	Figure 7.0-1	Key Elements to Consider during Development of a Vaccine Strategy..... 38